Other Name(s): hTERT, telomerase reverse transcriptase
Drug Target Analysis Report Drug Target Analysis Report Content

About the Target

The provided context information discusses the function and regulation of telomerase reverse transcriptase (TERT). TERT is a crucial component of telomerase holoenzymes, which play a role in telomere maintenance and cell immortalization. Telomerase assembly and function rely on various factors, including telomerase holoenzyme proteins and chaperones [1]. TERT has been observed to have extracurricular mechanisms, including its involvement in tumor invasion and progression by regulating miRNAs like miR500A [2]. Knockdown of TERT expression has also been shown to affect cell viability and proliferation [3]. Regulatory factors, such as IPO13 and RFPL3, mediate the expression and transport of TERT to the nucleus [3]. Additionally, the genomic structure of TERT exhibits specific elements and histone markers that impact its regulation [4]. The binding of other proteins like HuR to TERT-associated RNA (TERC) affects telomerase activity through TERC methylation [5]. Overall, these findings provide insights into the complex mechanisms and regulation of TERT in various cellular processes and diseases.
Based on the provided context, here is a comprehensive summary of key viewpoints related to hTERT (synonymous with TERT):

CRISPR Interference System: The schematic describes the use of the CRISPR interference system to selectively control the expression of downstream output sgRNAs in bladder cancer cells. The system involves combining the dCas9-KRAB system, hTERT, and the hUPII promoter to regulate gene expression [6].

Mechanism of CRISPR-dCas9-KRAB System: The mechanism of the CRISPR-dCas9-KRAB system is elaborated in parts A, B, C, and D of the provided context. In part A, CBP sgRNA and p300 sgRNA mature and remain in the nucleus. They then combine with the dCas9-KRAB protein to suppress the transcription of CBP and P300 genes. In part B, only p300 sgRNA matures and combines with dCas9-KRAB protein to inhibit p300 transcription. Parts C and D provide further insights into the mechanism of the CRISPR-dCas9-KRAB system [6].

Gene Suppression in Bladder Cancer Cells: The CRISPR-dCas9-KRAB system is specifically designed to control gene expression in bladder cancer cells. By targeting specific sgRNAs and using hTERT in combination with the dCas9-KRAB system, the system aims to suppress the transcription of target genes involved in bladder cancer [6].

Overall, the provided information focuses on the CRISPR interference system and its mechanism utilizing dCas9-KRAB, hTERT, and specific sgRNAs to regulate gene expression in bladder cancer cells. It showcases the potential of this system to selectively control downstream gene transcription, particularly in the context of CBP and P300 genes [6].

Figure [1]

Figure [2]

Figure [3]

Figure [4]

Figure [5]

Figure [6]

Note: If you are interested in the full version of this target analysis report, or if you'd like to learn how our AI-powered BDE-Chem can design therapeutic molecules to interact with the TERT target at a cost 90% lower than traditional approaches, please feel free to contact us at BD@silexon.ai.

More Common Targets

ABCB1 | ABCG2 | ACE2 | AHR | AKT1 | ALK | AR | ATM | BAX | BCL2 | BCL2L1 | BECN1 | BRAF | BRCA1 | CAMP | CASP3 | CASP9 | CCL5 | CCND1 | CD274 | CD4 | CD8A | CDH1 | CDKN1A | CDKN2A | CREB1 | CXCL8 | CXCR4 | DNMT1 | EGF | EGFR | EP300 | ERBB2 | EREG | ESR1 | EZH2 | FN1 | FOXO3 | HDAC9 | HGF | HMGB1 | HSP90AA1 | HSPA4 | HSPA5 | IDO1 | IFNA1 | IGF1 | IGF1R | IL17A | IL6 | INS | JUN | KRAS | MAPK1 | MAPK14 | MAPK3 | MAPK8 | MAPT | MCL1 | MDM2 | MET | MMP9 | MTOR | MYC | NFE2L2 | NLRP3 | NOTCH1 | PARP1 | PCNA | PDCD1 | PLK1 | PRKAA1 | PRKAA2 | PTEN | PTGS2 | PTK2 | RELA | SIRT1 | SLTM | SMAD4 | SOD1 | SQSTM1 | SRC | STAT1 | STAT3 | STAT5A | TAK1 | TERT | TLR4 | TNF | TP53 | TXN | VEGFA | YAP1